Results 121 to 130 of about 5,967 (167)

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. [PDF]

Br J Cancer
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.   +21 more
europepmc   +1 more source

Durable Response in <i>NTRK</i> Fusion-Positive Advanced Salivary Gland Tumor: A Case Report. [PDF]

Case Rep Oncol
Oblitas Alca GA, Ayala Loma L, González L, Vega P, Negrón Abril YL, Sumarriva D.   +5 more
europepmc   +1 more source

Single-Institution Experience of Larotrectinib Therapy for Patients With NTRK Fusion-Positive Thyroid Carcinoma. [PDF]

J Endocr Soc
Elghawy O, Barsouk A, Heidlauf A, Chen S, Cohen RB, Sun L.   +5 more
europepmc   +1 more source

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion-positive glioblastoma. [PDF]

Front Oncol
Turco L, Della Monica R, Giordano P, Cuomo M, Biazzo M, Mateu B, Di Liello R, Daniele B, Normanno N, De Luca A, Rachiglio AM, Chiaramonte C, Giugliano FM, Chiariotti L, Catapano G, Coretti L, Lembo F.   +16 more
europepmc   +1 more source

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric <i>NTRK</i> Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). [PDF]

J Clin Oncol
Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, Ronan J, Rudzinski ER, Memken A, Robinson K, Sorger J, Reid JM, Bhatla T, Crompton BD, Church AJ, Fox E, Weigel BJ.   +16 more
europepmc   +1 more source

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. [PDF]

J Manag Care Spec Pharm
Willis C, Au T, Hejazi A, Griswold C, Schabath MB, Thompson J, Malhotra J, Federman N, Ko G, Appukkuttan S, Warnock N, Kong SX, Hocum B, Brixner D, Stenehjem D.   +14 more
europepmc   +1 more source